NCT04769050: Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Therapeutic Antibody, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated central nervous system (CNS) metastases including brain or leptomeningeal metastases; Patients who have received more than 1 prior lines of systemic chemotherapy for metastatic breast cancer

Comments are closed.

Up ↑